Cancer Monoclonal Antibodies Market to 2015

• Publication date: March 2012

Globally, cancer is one of the leading causes of death, and accounted for almost 13% of total deaths in 2008. The cases of lung and breast cancers are expected to grow rapidly in the coming years. In order to treat the life-threatening disease more efficiently and with enhanced specificity, monoclonal antibodies have become the most widely used cancer therapy. As per the findings of our new research report, cancer monoclonal antibodies provide hi...

Globally, cancer is one of the leading causes of death, and accounted for almost 13% of total deaths in 2008. The cases of lung and breast cancers are expected to grow rapidly in the coming years. In order to treat the life-threatening disease more efficiently and with enhanced specificity, monoclonal antibodies have become the most widely used cancer therapy. As per the findings of our new research report, cancer monoclonal antibodies provide high specificity to treat tumors and several formats exist for the types of cancer monoclonal antibodies available.

According to “Cancer Monoclonal Antibodies Market to 2015”, cancer monoclonal antibodies have evolved greatly from the first time they were implemented, and have created a strong demand since then. In the recent time, some very important monoclonal antibodies, such as Yervoy (ipilimumab) have entered the market. Our study expects that these antibodies will consume the share of leading monoclonal antibody products in the coming years.

Our research observed that the strong demand for effective cancer treatments and high prevalence are driving the cancer monoclonal antibodies market which is anticipated to grow at a CAGR of around 7% during 2012-2015. While research and innovation in this field have been growing exorbitantly, the industry has witnessed a large number of consolidation activities. In the report, we have also studied how technological advancements and a subsequent increase in number of approvals are influencing the market growth.

During the study of latest industry trends and drivers, we observed that conjugated cancer antibody therapies offer efficient cancer treatments. Besides, bispecific antibodies (BiAbs) present a unique opportunity to redirect immune effector cells to kill cancer cells. Our report covers the analysis of the entire monoclonal antibody market for cancer, and presents market forecasts for leading products. The geographic analyses for key markets, carried out in the research, foresee that the US and Europe will continue holding significant market shares, and
Japan will exhibit unaltered double digit growth.

In our research report, we have conducted a comprehensive pipeline analysis of the expected cancer monoclonal antibodies and their phase of development. We found that maximum products are expected in the field of breast cancer in near future. The study discusses in detail the key market players, their business activities, key monoclonal antibody products which are available in the market and in pipeline. Overall, we expect the cancer monoclonal antibody market to show stupendous growth and great evolution in the coming years.

Biopharmaceutical Industry in Japan

1. Analyst View
2. Research Methodology
3. The Global Burden of Cancer
3.1 Cancer - A Leading Cause of Death
3.2 Current and Future Cancer Cases: By Type and Geography
3.3 Common Causes of Cancer
4. Global Cancer Market Outlook to 2015
4.1 Current and Future Growth
4.2 Analysis by Therapeutic Areas
5. Monoclonal Antibodies: Introduction and Working
5.1 Types of Mabs
5.1.1 Murine Antibodies
5.1.2 Chimeric and Humanized Antibodies
5.1.3 Fully Human Antibodies
5.2 Conjugated Cancer Therapies using MAbs
5.2.1 Radioimmunotherapy
5.2.2 Antibody-directed Enzyme Pro-drug Therapy (ADEPT)
5.2.3 Immunoliposomes
5.2.4 Immunotoxin
5.2.5 Immunocytokine
5.3 mAb Therapies
5.3.1 Avastin/Bevacizumab
5.3.2 Rituxan/Rituximab
5.3.3 Herceptin/Trastuzumab
5.3.4 Erbitux/Cetuximab
5.3.5 Vectibix/Panitumumab
5.3.6 Campath/Alemtuzumab
5.3.7 Zevalin/ Ibritumomab
5.3.8 Bexxar/Tositumomab
5.3.9 Arzerra/Ofatumumab
6. Industry Trends and Drivers
6.1 Strategic Activity Building Up in the Market
6.2 New Approvals Showing Promising Future
6.3 Bispecific Antibodies: Emerging Therapeutic Treatment
6.4 Japan Gearing-up for Cancer Antibodies
7. Global Anti-Neoplastic mAbs Market Outlook to 2015
7.1 Market Size
7.2 Anti-Neoplastic mAbs: Approval History and Market Share
7.3 Anti-Neoplastic mAbs: Current and Future Market Size
7.3.1 Avastin (Bevacizumab)
7.3.2 MabThera/Rituxan (Rituximab)
7.3.3 Herceptin (Trastuzumab)
7.3.4 Erbitux (Cetuximab)
7.3.5 Vectibix (Panitumumab)
7.4 Country-Level Analysis
7.4.1 US
7.4.2 Japan
7.4.3 Europe
7.5 Market Share of Key Players
8. Pipeline Analysis for Anti-Neoplastic Monoclonal Antibodies
9. Competitive Landscape
9.1 Roche
9.2 Immunomedics
9.3 Bristol-Myers Squibb
9.4 AstraZeneca
9.5 Eli Lilly
9.6 Amgen

List of Figures:

Figure 3-1: Global - Leading Causes of Non-Communicable Deaths (%), 2008
Figure 3-2: Global - Number of Cancer Deaths (Million), 2002, 2020 & 2030
Figure 3-3: Global - Number of New Cancer Cases (Million), 2009 & 2020
Figure 3-4: Global - New Cancer Cases by Region (%), 2009
Figure 3-5: Global - Forecast for the New Cancer Cases by Region (%), 2020
Figure 4-1: Global - Cancer Market (Billion US$), 2011-2015
Figure 4-2: Global - Cancer Market by Player (%), 2011
Figure 4-3: Global - Cancer Market by Therapeutic Segment (%), 2011
Figure 5-1: Types of Monoclonal Antibodies
Figure 5-2: Hybridoma Technology for Mouse-derived Monoclonal Antibodies
Figure 7-1: Global - Anti-Neoplastic mAbs Market (Billion US$), 2011-2015
Figure 7-2: Global - Anti-Neoplastic mAbs Market by Product (%), 2011
Figure 7-3: Global - Avastin Sales (Billion US$), 2011-2015
Figure 7-4: Global - MabThera/Rituxan Sales (Billion US$), 2011-2015
Figure 7-5: Global - Herceptin Sales (Billion US$), 2011-2015
Figure 7-6: Global - Erbitux Sales (Billion US$), 2011-2015
Figure 7-7: Global - Vectibix Sales (Million US$), 2011-2015
Figure 7-8: Global - Anti-Neoplastic mAbs Market by Country/Region (%), 2011
Figure 7-9: US - Anti-Neoplastic mAbs Market (Billion US$), 2011-2015
Figure 7-10: Japan - Anti-Neoplastic mAbs Market (Billion US$), 2011-2015
Figure 7-11: Europe - Anti-Neoplastic mAbs Market (Billion US$), 2011-2015
Figure 7-12: Global - Anti-Neoplastic mAbs Market by Player (%), 2011
Figure 8-1: Global - Breakup of Anti-Neoplastic mAbs in Pipeline by Phase

List of Tables:

Table 3-1: Global - Number of New Cancer Cases by Type and Geography (2009)
Table 3-2: Global - Forecast for the Number of New Cancer Cases by Type and Geography (2020)
Table 4-1: Global - Revenues from Major Therapy Areas (Billion US$), 2011 & 2015
Table 7-1: Global - List of FDA Approved Anti-Neoplastic mAbs with Year and Indication
Table 7-2: US - Forecast for the Number of Cancer Cases and Deaths by Types (2012)
Table 7-3: US - Anti-Neoplastic mAbs Expenditure in Clinics (Million US$), 2010 & 2011
Table 7-4: Japan - Number of Cancer Deaths by Type and Gender (2008 & 2009)
Table 7-5: Japan - Approval Date for Key Cancer mAbs
Table 7-6: EU - Number of Cancer Cases and Deaths by Type (2008)
Table 7-7: EU - Approval Date for Key Cancer mAbs
Table 8-1: Global - Anti-Neoplastic mAbs of Key Players in Pipeline
Table 8-2: Global - Anti-Neoplastic mAbs in Pipeline for Cancer Type by Rank
Table 9-1: Roche - Key Monoclonal Antibodies in Market
Table 9-2: Roche - Key Monoclonal Antibodies in Pipeline
Table 9-3: Immunomedics - Key Monoclonal Antibodies in Market
Table 9-4: Immunomedics - Key Monoclonal Antibodies in Pipeline
Table 9-5: Bristol-Myers Squibb - Key Monoclonal Antibodies in Market
Table 9-6: Bristol-Myers Squibb - Key Monoclonal Antibodies in Pipeline
Table 9-7: AstraZeneca - Key Monoclonal Antibodies in Pipeline
Table 9-8: Eli Lilly - Key Monoclonal Antibodies in Market
Table 9-9: Eli Lilly - Key Monoclonal Antibodies in Pipeline
Table 9-10: Amgen - Key Monoclonal Antibodies in Market
Table 9-11: Amgen - Key Monoclonal Antibodies in Pipeline

Biopharmaceutical in Japan

Japan Pharmaceutical Exports - Blood, Antisera, Vaccines, Toxins And Cultures, Us$mn

• $ 250
• Industry data
• January 2013

Yearly, From 2002 To 2011
By Business Monitor International
Source: United Nations Comtrade Database DESA/UNSD, BMI

• Industries : Biopharmaceutical
• Countries : Japan

Japan Pharmaceutical Exports - Blood, Antisera, Vaccines, Toxins And Cultures, Jpymn

• $ 250
• Industry data
• January 2013

Yearly, From 2002 To 2011
By Business Monitor International
Source: United Nations Comtrade Database DESA/UNSD, BMI

• Industries : Biopharmaceutical
• Countries : Japan

Japan Pharmaceutical Imports - Blood, Antisera, Vaccines, Toxins And Cultures, Jpymn

• $ 250
• Industry data
• January 2013

Yearly, From 2002 To 2011
By Business Monitor International
Source: United Nations Comtrade Database DESA/UNSD, BMI

• Industries : Biopharmaceutical
• Countries : Japan

Japan Pharmaceutical Imports - Blood, Antisera, Vaccines, Toxins And Cultures, Us$mn

• $ 250
• Industry data
• January 2013

Yearly, From 2002 To 2011
By Business Monitor International
Source: United Nations Comtrade Database DESA/UNSD, BMI

• Industries : Biopharmaceutical
• Countries : Japan